A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS - ND
- Conditions
- Adult growth hormone deficiency AGHD .MedDRA version: 6.1Level: PTClassification code 10056438
- Registration Number
- EUCTR2005-005587-82-IT
- Lead Sponsor
- PFIZER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 136
1. Male and female patients between the ages of 25-60 yrs with severe AGHD as defined by Growth Hormone Research Society GRS Guidelines 3 . Patients may be included if they had idiopathic severe GHD in childhood, which is still present on re-testing, or if they have isolated GHD with evidence of hypothalamic/pituitary pathology. 2. Hypopituitary patients must be on adequate hormone replacement therapy for at least 6 months. Patients must be demonstrated to have adequate cortisol reserve or be on adequate glucocorticoid replacement therapy. 3. GH treated patients will have a minimum of 3 weeks washout and not longer than 4 weeks prior to dosing. 4. Written informed consent. 5. Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other program procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. AGHD patients with uncontrolled pituitary tumor growth. Patients with pituitary tumors must have demonstrated stable neuroimaging within 12 months of the screening visit. 2. Tumors within 3 mm of the optic chiasm. Patients with residual suprasellar disease, must be scanned within 3 months of the screening visit. 3. Serum ALT and/or AST / 1.5 times the upper limit of normal range ULN , or clinically significant hepatic disease. 4. Patients with diabetes mellitus. Impaired glucose tolerance without drug treatment is permissible. 5. Patients who drink more than 28 units per week 1 unit 1/2 pint of beer 285mL or 25mL of spirits or one glass 125mL of wine . 6. Patients with a history of clinically significant allergies, especially drug hypersensitivity. 7. Patients who have evidence of drug or substance abuse. 8. Patients who have donated blood or blood products during the previous two months or intend to donate blood or blood products during the study or for two months following the completion of the study. 9. Patients who have a positive screening for HIV, Hepatitis B surface antigen HBsAg or Hepatitis B core antibody HBcAb or anti-hepatitis C virus serology as determined by a multi-antigen EIA . 10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration, or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into this trial e.g.active malignant disease, morbid obesity BMI / 40 . 11. Pregnant or lactating women. 12. Female of child-bearing potential who is unwilling or unable to use adequate contraception to prevent pregnancy during the study. 13. Concomitant therapy with other investigational drugs or participation in another clinical trial in the last 6 months. 14. Requirement to use medication during the study that might interfere with the evaluation of the study drug.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To explore the safety, toleration and humoral response of PHA-794428 after multiple weekly injections in AGHD patients. To explore the dose response relationship of PHA-794428 after multiple weekly subcutaneous injections in AGHD patients.;Secondary Objective: To explore the PK/PD relationships with PHA-794428 after single and multiple injections.;Primary end point(s): Responder status at visits 9 week 4 and 14 week 7 , where responder is defined as a patient who has achieved an IGF-1 level above the mid-point of the age-related normal range.
- Secondary Outcome Measures
Name Time Method